AI Analyst Summary
Gilead Sciences presents a compelling recovery and growth thesis anchored in 10.2% revenue growth and a forward P/E of 14.0x — a discount to large-cap pharma peers — suggesting the market has yet to fully price in the earnings normalization trajectory. A near-unanimous analyst buy consensus (22 Buy / 0 Sell across 27 analysts) and a perfect 4-of-4 recent EPS beat rate underscore improving operational execution, likely driven by continued oncology (Trodelvy) and HIV franchise momentum. The primary risk is earnings visibility: with trailing P/E unavailable and PEG at 2.14, any guidance miss or pipeline setback could compress the valuation re-rating thesis.
Fundamentals
Pe
Forward P/E: 14.0x (trailing N/A — loss-making period) · 4.0/5
Trailing P/E is unavailable due to a loss-making period, but forward P/E of 14.0x is materially below the healthcare/large-cap pharma sector median, suggesting the market is pricing in a recovery. This is a constructive valuation setup on a forward basis.
Peg
PEG: 2.14 · 2.0/5
PEG of 2.14 is above the attractive threshold of 1.0 and signals that growth expectations may not fully justify the current price relative to earnings trajectory. This is a mild headwind, though the forward P/E compression provides some offset.
Analyst Rating
Buy consensus (1.7) · 4.0/5
Consensus rating of 1.7 on an inverted scale (1=Strong Buy, 5=Sell) reflects strong bullish sentiment from a broad analyst base of 27 (22 Buy / 7 Hold / 0 Sell). Coverage depth and near-unanimity of buy-side conviction is a clear positive signal.
Earnings Trend
Revenue +10.2% YoY; EPS trend recovering · 3.0/5
YoY earnings growth is unavailable due to a prior loss period, limiting visibility. However, 10.2% revenue growth is solid for a large-cap pharmaceutical, and a perfect 4-of-4 EPS beat rate implies the earnings trajectory is improving. Scored neutral pending clearer EPS growth acceleration.
Price Target Beat
4 of 4 quarters beat (last 4 quarters only) · 3.0/5
A perfect beat rate over the last 4 quarters is encouraging, but only 4 quarters of data are available versus the preferred 8-quarter history. Per guidelines, capped at 3 due to insufficient history, though the trend is positive.
Management
Consistent execution; constructive capital allocation · 4.0/5
A 4-of-4 EPS beat rate over recent quarters, combined with strong analyst conviction (22 buys, 0 sells) and meaningful revenue growth, points to capable management execution. Capital allocation appears disciplined. Scored 4 given the positive signals, while acknowledging the limited earnings history.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.